Insider Selling: Immunovant (NASDAQ:IMVT) CEO Sells 14,229 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT) CEO Eric Venker sold 14,229 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $24.10, for a total value of $342,918.90. Following the completion of the sale, the chief executive officer owned 19,561 shares of the company’s stock, valued at $471,420.10. This trade represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immunovant Stock Performance

Shares of NASDAQ:IMVT remained flat at $24.50 during midday trading on Friday. The stock had a trading volume of 2,013,045 shares, compared to its average volume of 1,302,727. Immunovant, Inc. has a 52-week low of $12.72 and a 52-week high of $29.25. The stock has a market cap of $4.99 billion, a P/E ratio of -9.11 and a beta of 0.67. The company has a 50-day simple moving average of $25.78 and a two-hundred day simple moving average of $23.41.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Friday, February 6th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.11. During the same quarter in the previous year, the business posted ($0.76) earnings per share. On average, sell-side analysts forecast that Immunovant, Inc. will post -2.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IMVT. Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research note on Tuesday, January 6th. The Goldman Sachs Group lifted their price objective on Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Guggenheim boosted their price objective on Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Sanford C. Bernstein initiated coverage on Immunovant in a report on Friday, March 20th. They set a “market perform” rating and a $28.00 target price for the company. Finally, Truist Financial raised their target price on Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.00.

Key Stories Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Management highlights brepocitinib program expansion as a strategic response, signaling a shift of R&D and commercial focus toward the oral JAK/TYK2 asset that could partially offset the batoclimab setback; this gives investors a tangible alternative program to watch for future value creation. Immunovant Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
• Neutral Sentiment: Company released additional corporate materials/slideshow discussing the pipeline and Phase 3 update; these materials provide management context but don’t replace the clinical outcomes that move valuation. Monitor upcoming investor calls or detailed data disclosures for clarification. Slideshow: Brepocitinib and Batoclimab Phase III Data Update
• Negative Sentiment: Batoclimab failed to meet primary endpoints in Phase 3 TED trials — multiple outlets report the late‑stage miss and its immediate negative market implications; this reduces the expected near‑term revenue runway from that program and increases execution risk. Reuters: Treatment for eye disease fails late‑stage trial
• Negative Sentiment: CEO Eric Venker sold 14,229 shares at an average $24.10 (a ~42% reduction in his holdings), a disclosure that can amplify negative sentiment after the clinical setback; insiders selling after disappointing news may concern some investors. SEC Form 4: Insider Sale

Institutional Investors Weigh In On Immunovant

A number of large investors have recently modified their holdings of IMVT. Two Seas Capital LP raised its position in shares of Immunovant by 37.1% in the second quarter. Two Seas Capital LP now owns 2,252,772 shares of the company’s stock valued at $36,044,000 after buying an additional 610,000 shares during the last quarter. Granahan Investment Management LLC boosted its position in Immunovant by 24.9% during the third quarter. Granahan Investment Management LLC now owns 266,221 shares of the company’s stock worth $4,291,000 after acquiring an additional 53,133 shares during the last quarter. Capital Fund Management S.A. acquired a new position in Immunovant during the second quarter worth about $888,000. Assenagon Asset Management S.A. purchased a new stake in Immunovant during the 3rd quarter valued at about $3,308,000. Finally, Alpine Global Management LLC grew its stake in Immunovant by 4.9% during the 3rd quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company’s stock valued at $44,406,000 after acquiring an additional 128,039 shares in the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.